Wrapmanager Inc. Trims Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Wrapmanager Inc. lowered its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 41.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 22,356 shares of the medical technology company’s stock after selling 16,043 shares during the period. Wrapmanager Inc.’s holdings in Alphatec were worth $205,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ATEC. State Street Corp boosted its stake in shares of Alphatec by 10.1% in the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after acquiring an additional 287,350 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after purchasing an additional 297,850 shares in the last quarter. Royce & Associates LP boosted its stake in Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after purchasing an additional 165,954 shares during the period. New York State Common Retirement Fund grew its holdings in Alphatec by 21.2% during the 4th quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company’s stock valued at $11,037,000 after buying an additional 210,519 shares in the last quarter. Finally, Walleye Capital LLC grew its holdings in Alphatec by 3.2% during the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock valued at $5,902,000 after buying an additional 32,529 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of NASDAQ:ATEC opened at $10.56 on Wednesday. The firm has a fifty day simple moving average of $10.52 and a two-hundred day simple moving average of $8.33. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $15.41. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The stock has a market capitalization of $1.50 billion, a P/E ratio of -8.25 and a beta of 1.43.

Insider Activity at Alphatec

In other news, COO Scott Lish sold 27,453 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the transaction, the chief operating officer now owns 867,677 shares of the company’s stock, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 222,376 shares of company stock valued at $2,557,148. Insiders own 22.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ATEC. Needham & Company LLC upped their target price on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. Finally, Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.